Allogene Therapeutics, Inc. (ALLO) stock forecast and price target
Price $0.84 · data as of November 13, 2026
12-month price target
Average target$9.00
Upside / downside+973.1%
Analysts9
ConsensusStrong buy
Low $4.00Average $9.00High $14.00
Gold marker: average target · white marker: today’s price ($0.84)
Analyst ratings
Strong buy 3Buy 8Hold 1Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.58 | +32.6% | $4M |
| Next fiscal year ends December 31, 2027 | $-0.61 | −6.1% | $12M |
| Next quarter ends December 31, 2026 | $-0.15 | +11.5% | $2220 |
| Quarter after ends March 31, 2027 | $-0.14 | +24.1% | $3330 |
Consensus of the analysts covering Allogene Therapeutics, updated daily. In the last 30 days 1 estimates were raised and 1 lowered.
Frequently asked questions
What is the Allogene Therapeutics stock price target?
The average 12-month target from 9 analysts is $9.00, 973.1% above the current price of $0.84 Targets range from $4.00 to $14.00.
Is Allogene Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (3 strong buy, 8 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Allogene Therapeutics expected to earn?
Analysts expect EPS of $-0.58 for the fiscal year ending December 31, 2026 and $-0.61 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.